Statistics for CytomX Therapeutics (id:8339 CTMX)
Valuation metrics
Market cap
69.65M
Enterprise value
-39,179,680.00
Trailing P/E (ttm)
5.56
Forward P/E
-1.53
PEG ratio
-1.53
Price/Sales (ttm)
0.55
Price/Book (mrq)
-3.23
Enterprise Value/Revenue
-0.31
Enterprise Value/EBITDA
-4.58
Overview
Shares outstanding
78.26M
Float
66.48M
Shares short
5.67M
% Held by insiders
0.01%
% Held by institutions
0.65%
Average volume (10 days)
975.16K
Average volume (90 days)
Price summary
52-Week low
0.83
52-Week high
5.85
52-Week change
-49.44%
Beta
1.06
50-Day moving average
1.09
200-Day moving average
1.59
Dividends and splits
Forward annual dividend rate
Forward annual dividend yield
Trailing annual dividend rate
0.00%
Trailing annual dividend yield
0.00
5-Year annual dividend yield
Payout ratio
0.00
Dividend date
Ex-dividend date
Last split factor
2:1
Last split date
Financials
Fiscal yearFiscal year ends
December 31th, 2023
Most recent quarter (mrq)
September 30th, 2024
Profitability
Profit margin
10.92%
Operating margin
12.30%
Operational effectiveness
Return on assets
2.33%
Return on equity
1.20%
Income statement
Revenue (ttm)
1.52
Revenue per share (ttm)
1.52
Quarterly revenue growth (yoy)
0.92
Gross profit (ttm)
0.00
EBITDA
8.55M
Net income to common (ttm)
13.83M
Diluted EPS (ttm)
0.16
Quarterly earnings growth (yoy)
91.70%
Balance sheet
Total cash (mrq)
117.59M
Total cash per share (mrq)
1.50
Total debt (mrq)
10.60M
Total Debt/Equity (mrq)
-0.45
Current ratio (mrq)
104.20%
Book value per share (mrq)
-0.30
Cash flow
Cash flow statement
-88,286,000.00
Levered free cash flow (LFCF)
-13,728,250.00